112 related articles for article (PubMed ID: 16542298)
1. Hepatitis C treatment of veterans with psychiatric illness.
Rifai MA; Loftis JM; Hauser P
Am J Gastroenterol; 2006 Mar; 101(3):673-4; author reply 674-5. PubMed ID: 16542298
[No Abstract] [Full Text] [Related]
2. [Treatment of chronic hepatitis C].
Bell H; Dalgard O; Bjøro K; Hellum KB; Myrvang B
Tidsskr Nor Laegeforen; 2002 Apr; 122(9):926-8. PubMed ID: 12082838
[No Abstract] [Full Text] [Related]
3. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection.
Bini EJ; Bräu N; Currie S; Shen H; Anand BS; Hu KQ; Jeffers L; Ho SB; Johnson D; Schmidt WN; King P; Cheung R; Morgan TR; Awad J; Pedrosa M; Chang KM; Aytaman A; Simon F; Hagedorn C; Moseley R; Ahmad J; Mendenhall C; Waters B; Strader D; Sasaki AW; Rossi S; Wright TL
Am J Gastroenterol; 2005 Aug; 100(8):1772-9. PubMed ID: 16086714
[TBL] [Abstract][Full Text] [Related]
4. Interferon for hepatitis C patients with psychiatric disorders.
Asnis GM; De La Garza R; Rego SA; Henderson MA; Reinus JF
Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569920
[No Abstract] [Full Text] [Related]
5. Chronic hepatitis C virus infection.
Flamm SL
JAMA; 2003 May; 289(18):2413-7. PubMed ID: 12746366
[No Abstract] [Full Text] [Related]
6. [Chronic hepatitis C virus infection: always treat!--Contra].
Blum HE
Dtsch Med Wochenschr; 2002 Sep; 127(36):1841. PubMed ID: 12215932
[No Abstract] [Full Text] [Related]
7. Interferon for hepatitis C patients with psychiatric disorders.
Rifai MA; Bozorg B; Rosenstein DL
Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
[No Abstract] [Full Text] [Related]
8. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.
Loftis JM; Matthews AM; Hauser P
Drugs; 2006; 66(2):155-74. PubMed ID: 16451091
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus infection.
Himelhoch S
N Engl J Med; 2001 Nov; 345(19):1426-7; author reply 1427-8. PubMed ID: 11794184
[No Abstract] [Full Text] [Related]
10. Peginterferon and ribavirin for hepatitis C.
Evoli A; Servidei S
N Engl J Med; 2007 Mar; 356(12):1269-70; author reply 1271. PubMed ID: 17380575
[No Abstract] [Full Text] [Related]
11. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
[TBL] [Abstract][Full Text] [Related]
12. Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study.
Chang SC; Hung CT; Li SF; Lee HM; Chung YC; Pai LW; Yang SS
J Formos Med Assoc; 2015 Sep; 114(9):829-34. PubMed ID: 24090634
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project.
Lindenburg CE; Lambers FA; Urbanus AT; Schinkel J; Jansen PL; Krol A; Casteelen G; van Santen G; van den Berg CH; Coutinho RA; Prins M; Weegink CJ
Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):23-31. PubMed ID: 21042221
[TBL] [Abstract][Full Text] [Related]
14. The effect of pegylated interferon-alpha2b and ribavirin on posttraumatic stress disorder symptoms.
Dieperink E; Leskela J; Dieperink ME; Evans B; Thuras P; Ho SB
Psychosomatics; 2008; 49(3):225-9. PubMed ID: 18448777
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
Giannini EG; Marenco S; Fazio V; Pieri G; Savarino V; Picciotto A
Liver Int; 2012 Aug; 32(7):1113-9. PubMed ID: 22471814
[TBL] [Abstract][Full Text] [Related]
16. Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C.
Vukotic R; Gamal N; Andreone P
Dig Liver Dis; 2015 Feb; 47(2):151-6. PubMed ID: 25483909
[TBL] [Abstract][Full Text] [Related]
17. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.
Raison CL; Broadwell SD; Borisov AS; Manatunga AK; Capuron L; Woolwine BJ; Jacobson IM; Nemeroff CB; Miller AH
Brain Behav Immun; 2005 Jan; 19(1):23-7. PubMed ID: 15581735
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
[TBL] [Abstract][Full Text] [Related]
19. Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: results from a retrospective chart review.
Nelligan JA; Loftis JM; Matthews AM; Zucker BL; Linke AM; Hauser P
J Clin Psychiatry; 2008 May; 69(5):810-6. PubMed ID: 18426262
[TBL] [Abstract][Full Text] [Related]
20. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients.
Talal AH; LaFleur J; Hoop R; Pandya P; Martin P; Jacobson I; Han J; Korner EJ
Aliment Pharmacol Ther; 2013 Feb; 37(4):473-81. PubMed ID: 23289640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
